加速的肺功能下降与心血管结局相关性的系统综述
该系统综述检索MEDLINE、Embase和PubMed至2026年5月,纳入15项研究(12个一般人群队列、2个职业队列、1个慢阻肺队列),评估肺功能纵向变化与心血管疾病的关系。一般/职业人群中加速肺功能下降与心血管风险增加一致相关,FEV₁的HR为1.07-1.36,FVC为1.06-1.33;职业队列中肺功能下降与心血管死亡风险升高相关(HR 2.05-2.59),但一般人群的心血管死亡关联尚不明确。
要点
- 加速肺功能下降与心血管风险增加一致相关,FEV₁的HR为1.07-1.36。
- 职业队列中肺功能下降与心血管死亡风险升高相关,HR为2.05-2.59。
- 一般人群中肺功能下降与心血管死亡的关联尚不明确。
核心结论
- 在老龄化人群中,追踪肺功能下降速率可能有助于识别慢阻肺风险者及心血管疾病风险者。
研究设计与样本
- 系统综述检索MEDLINE、Embase和PubMed自建库至2026年5月,纳入评估成人肺功能纵向变化与心血管疾病关系的研究。
- 共鉴定6772项研究,15篇文献符合纳入标准:12个一般人群队列、2个职业队列和1个慢阻肺队列。
- 使用非随机干预研究偏倚风险评估工具评价研究质量,结果采用叙述性综合。
主要发现
- 一般/职业人群中加速肺功能下降与心血管风险增加一致相关,方向趋势一致为正向。
- FEV₁加速下降的心血管风险HR范围为1.07-1.36,FVC为1.06-1.33。
- 心血管疾病相关生物标志物、危险因素和亚临床心血管表型也观察到类似趋势,例如加速FEV₁下降的HR为1.04-1.66。
- 一般人群中加速肺功能下降与心血管疾病死亡的关联尚不确定。
- 两个职业队列中肺功能下降与心血管疾病死亡风险升高相关,HR为2.05-2.59。
关键数值与推荐
- FEV₁加速下降与心血管风险的HR范围为1.07-1.36。
- FVC加速下降与心血管风险的HR范围为1.06-1.33。
- 加速FEV₁下降与心血管生物标志物、危险因素及亚临床表型的HR范围为1.04-1.66。
- 职业队列中肺功能下降与心血管疾病死亡的HR范围为2.05-2.59。
临床怎么用
- 在老龄化人群中,监测肺功能下降速率可能同时提示慢阻肺和心血管疾病风险。
局限性
- 一般人群中加速肺功能下降与心血管疾病死亡的关联尚不明确。
- 报告了吸烟等潜在效应修饰因素,但具体影响未详细阐述。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Emerging evidence suggests that lung function decline may be linked to cardiovascular disease (CVD), but this has not been synthesised to date. This review aims to synthesise the current evidence on accelerated lung function decline and cardiovascular outcomes. METHODS: We systematically searched MEDLINE, Embase and PubMed from inception to May 2026 for studies evaluating longitudinal changes in lung function in adults in relation to CVD. Study quality was assessed using the Risk Of Bias In Non-randomised Studies of Exposure tool, and findings were synthesised narratively. FINDINGS: Of 6772 studies identified from the search, 15 publications met the inclusion criteria: 12 general population cohorts, 2 occupational cohorts and 1 chronic obstructive pulmonary disease (COPD) cohort. In the general/occupational population, accelerated lung function decline was consistently associated with increased cardiovascular risk, with a uniformly positive directional trend and HRs ranging from 1.07 to 1.36 for forced expiratory volume in 1 s (FEV₁) and 1.06 to 1.33 for forced vital capacity. Similar trends were observed for CVD-related biomarkers, risk factors and subclinical cardiovascular phenotypes (eg, HRs 1.04-1.66 for accelerated FEV1 decline). Potential effect modifiers of these associations such as smoking were reported. However, the association between accelerated lung function decline and CVD mortality in the general population remains inconclusive. In two occupational cohorts, lung function decline was associated with higher CVD mortality risk (HRs 2.05-2.59). INTERPRETATION: In ageing populations, tracking the rate of lung function decline may help identify not only those at risk of COPD but also those at risk of CVD.
引用
- Li J, Qian Y, Perret J, et al. Associations between accelerated lung function decline and cardiovascular outcomes: a systematic review. Thorax. 2026. PMID: 42716782. doi:10.1136/thorax-2026-225507
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。